Actualités Oncocyte Corporation - OCX | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Annual Report (10-k)

0001642380 false FY

Oncocyte Announces Reduction in Force

IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF...

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic...

Current Report Filing (8-k)

0001642380 false 0001642380 2023-04-03 2023-04-03 iso4217:USD xbrli:shares...

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the...

Notification That Annual Report Will Be Submitted Late (nt 10-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

0001642380 false 0001642380 2023-03-31 2023-03-31 iso4217:USD xbrli:shares...

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oncocyte Corporation (OCX)

Votre Hub pour des idées et discussions en direct en temps réel

OCX Actualités

Annual Report (10-k)

Oncocyte Announces Reduction in Force

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Current Report Filing (8-k)

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

Notification That Annual Report Will Be Submitted Late (nt 10-k)

Current Report Filing (8-k)

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Current Report Filing (8-k)

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oncocyte Corporation (OCX) Actualités

Oncocyte Corporation (OCX)

Votre Hub pour des idées et discussions en direct en temps réel

OCX Actualités

Annual Report (10-k)

Oncocyte Announces Reduction in Force

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Current Report Filing (8-k)

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

Notification That Annual Report Will Be Submitted Late (nt 10-k)

Current Report Filing (8-k)

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Current Report Filing (8-k)

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application